Multiple Sclerosis- Upcoming Novel Therapies Will Act as Market Drivers

By , in PR PR Health on .

New Delhi, India — 12/20/2017 — Multiple sclerosis (MS) is a potentially disabling disease of the brain and spinal cord in which the immune system attacks the myelin sheath. The disease can cause the nerves to weaken or become permanently damaged. Although the exact cause is unknown, the disease is considered to be an autoimmune disease. There are mainly four types of MS namely Relapsing-remitting multiple sclerosis (RRMS), Secondary-progressive multiple sclerosis (SPMS), Primary-progressive multiple sclerosis (PPMS), Benign multiple sclerosis. MS typically begins between the ages of 20 and 40 years and it is the leading cause of non-traumatic disability in young adults.

According to the latest report of DelveInsight, “Multiple Sclerosis – Market Insights, Epidemiology and Market Forecast 2025”, Multiple sclerosis affects approximately 400,000 people in the United States and 2.5 million worldwide. The prevalence of MS is higher in the US (140 per 100,000) as compared to that of Europe (108 per 100,000). The global prevalent cases of Multiple Sclerosis has increased from 2.1 million in 2008 to 2.3 million in 2013.

As per the World Health Organization (WHO) report, the median estimated global prevalence for MS is 30 cases per 100,000 population and the estimated incidence is approximately 2.5 cases per 100,000 population. The market revenue of Multiple Sclerosis is currently accounted by several approved therapies, some of which are dimethyl fumarate (Tecfidera; Biogen), Natalizumab (Tysabri; Biogen), Gilenya (Novartis), Extavia (Novartis), and Aubagio (Sanofi). Majority of the developer companies are now focused on novel approaches to treat all forms of MS. Some potential therapies under development for the treatment of MS are Daclizumab (Biogen), Ofatumumab (Novartis Pharmaceuticals), Ponesimod (Actelion), Ozanimod (Celgene), and Ublituximab (TG Therapeutics, Inc.).

The latest report has covered a detailed description of Disease Diagnostics, Diagnosis Criteria, and Treatment. Competitive analysis providing complete Pipeline drugs profiling covering each and every phase of development with clinical trials data. Global market size of Multiple Sclerosis is provided for 2016 and 2025 to better understand the areas of improvement and growth opportunities in the market. Complete Epidemiology and patient population details are provided covering the 7MM to better understand the major market scenario. Region-wise Market analysis is also provided covering the 7MM to understand the major market scenario. Details about all the possible market drivers and barriers are also provided to better understand to plan the strategies accordingly.

Reasons to buy:

– The report will help in developing business strategies by understanding trends shaping and driving the Multiple Sclerosis market.

– To understand the future market competition in the Multiple Sclerosis market and Insight reviews of the key market drivers and barriers.

– Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.

– In-depth understanding of the pipeline development and recent happenings will provide a competitive edge over competitors.

Companies Covered:

– Novartis Pharmaceuticals
– Actelion Pharmaceuticals
– Teva Pharmaceutical
– Biogen
– Celgene
– Sanofi
– TG Therapeutics
And many others

Table of Contents:
1. Report Introduction
2. Multiple Sclerosis Market Overview at a Glance
2.1. Global Market Size of Multiple Sclerosis in 2016
2.2. Global Market Size of Multiple Sclerosis in 2025
3. Disease Background and Overview: Multiple Sclerosis
3.1. Introduction
3.2. Causes
3.3. Pathophysiology
3.4. Symptoms
3.5. Risk Factor
3.6. Diagnosis
4. Epidemiology and Patient Population
4.1. Assumptions and Caveats
4.2. Multiple Sclerosis Geography wise Prevalent Cases
4.2.1. 7MM Prevalent Cases of Multiple Sclerosis in 2016
4.2.2. 7MM Prevalent Cases of Multiple Sclerosis in 2025
4.3. United States
4.3.1. Prevalent Cases of Multiple Sclerosis in United States (2015-2025)
4.3.2. Age-Specific Prevalence of Multiple Sclerosis in United States (2015-2025)
4.3.3. Sex-Specific Prevalence of Multiple Sclerosis in United States (2015-2025)
4.3.4. Sub-type Specific Prevalence of Multiple Sclerosis in United States (2015-2025)
4.4. EU-5
4.4.1. Assumptions and Rationale
4.4.2. Germany
4.4.2.1. Prevalent Cases of Multiple Sclerosis in Germany (2015-2025)
4.4.2.2. Age-Specific Prevalence of Multiple Sclerosis in Germany (2015-2025)
4.4.2.3. Sex-Specific Prevalence of Multiple Sclerosis in Germany (2015-2025)
4.4.2.4. Sub-type Specific Prevalence of Multiple Sclerosis in Germany (2015-2025)
4.4.3. Italy
4.4.3.1. Prevalent Cases of Multiple Sclerosis in Italy (2015-2025)
4.4.3.2. Age-Specific Prevalence of Multiple Sclerosis in Italy (2015-2025)
4.4.3.3. Sex-Specific Prevalence of Multiple Sclerosis in Italy (2015-2025)
4.4.3.4. Sub-type Specific Prevalence of Multiple Sclerosis in Italy (2015-2025)
4.4.4. Spain
4.4.4.1. Prevalent Cases of Multiple Sclerosis in Spain (2015-2025)
4.4.4.2. Age-Specific Prevalence of Multiple Sclerosis in Spain (2015-2025)
4.4.4.3. Sex-Specific Prevalence of Multiple Sclerosis in Spain (2015-2025)
4.4.4.4. Sub-type Specific Prevalence of Multiple Sclerosis in Spain (2015-2025)
4.4.5. France
4.4.5.1. Prevalent Cases of Multiple Sclerosis in France (2015-2025)
4.4.5.2. Age-Specific Prevalence of Multiple Sclerosis in France (2015-2025)
4.4.5.3. Sex-Specific Prevalence of Multiple Sclerosis in France (2015-2025)
4.4.5.4. Sub-type Specific Prevalence of Multiple Sclerosis in France (2015-2025)
4.4.6. United Kingdom
4.4.6.1. Prevalent Cases of Multiple Sclerosis in UK (2015-2025)
4.4.6.2. Age-Specific Prevalence of Multiple Sclerosis in UK (2015-2025)
4.4.6.3. Sex-Specific Prevalence of Multiple Sclerosis in UK (2015-2025)
4.4.6.4. Sub-type Specific Prevalence of Multiple Sclerosis in UK (2015-2025)
4.5. Japan
4.5.1. Prevalent Cases of Multiple Sclerosis in Japan (2015-2025)
4.5.2. Age-Specific Prevalence of Multiple Sclerosis in Japan (2015-2025)
4.5.3. Sex-Specific Prevalence of Multiple Sclerosis in Japan (2015-2025)
4.5.4. Sub-type Specific Prevalence of Multiple Sclerosis in Japan (2015-2025)
5. Treatment Algorithm
5.1. United States
5.2. Europe
5.3. Japan
6. Marketed Products
6.1. Tecfidera: Biogen
6.1.1. Mechanism of action
6.1.2. Regulatory Milestones
6.1.3. Advantages and disadvantages
6.1.4. Safety and efficacy
6.1.5. Side effects
6.1.6. Product profile
6.2. Tysabri: Biogen
6.2.1. Mechanism of action
6.2.2. Regulatory Milestones
6.2.3. Advantages and disadvantages
6.2.4. Safety and efficacy
6.2.5. Side effects
6.2.6. Product profile
6.3. Copaxone: Teva Pharmaceutical
6.3.1. Mechanism of action
6.3.2. Regulatory Milestones
6.3.3. Advantages and disadvantages
6.3.4. Safety and efficacy
6.3.5. Side effects
6.3.6. Product profile
7. Key Emerging Therapies
7.1. Key Cross Competition
7.2. Ponesimod: Actelion Pharmaceuticals
7.2.1. Regulatory Milestones
7.2.2. Clinical Development
7.2.3. Product Profile
7.2.4. Clinical Pipeline Activity
7.2.4.1. Ongoing Trials Information
7.2.4.2. Clinical Trial by Phase
7.3. Ofatumumab: Novartis Pharmaceuticals
7.3.1. Regulatory Milestones
7.3.2. Clinical Development
7.3.3. Product Profile
7.3.4. Clinical Pipeline Activity
7.3.4.1. Ongoing Trials Information
7.3.4.2. Clinical Trial by Phase
8. Multiple Sclerosis Market Size
8.1. Key Findings
8.2. Market Size: Assumptions and Forecast Parameters
8.3. Total 7MM Multiple Sclerosis Market Analysis
8.3.1. Overview of Total Multiple Sclerosis Market (2015-2025)
9. 7MM Multiple Sclerosis: Country-Wise Market Analysis
9.1. United States Market Size
9.1.1. Market Analysis
9.1.2. Emerging therapies analysis: Impact on the market
9.2. Germany Market Size
9.2.1. Market Analysis
9.2.2. Emerging therapies analysis: Impact on the market
9.3. France Market Size
9.3.1. Market Analysis
9.3.2. Emerging therapies analysis: Impact on the market
9.4. United Kingdom Market Size
9.4.1. Market Analysis
9.4.2. Emerging therapies analysis: Impact on the market
9.5. Spain Market Size
9.5.1. Market Analysis
9.5.2. Emerging therapies analysis: Impact on the market
9.6. Italy Market Size
9.6.1. Market Analysis
9.6.2. Emerging therapies analysis: Impact on the market
9.7. Japan Market Size
9.7.1. Market Analysis
9.7.2. Emerging therapies analysis: Impact on the market
10. Report Methodology
10.1. Sources Used
11. Consulting Services
12. Disclaimer

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. We support companies by providing end to end comprehensive solutions to improve their performance and in making a long-lasting decision for their businesses.

We advise leading decision makers on their critical issues and opportunities; Research & Development, Strategy Making, Commercial, Operations, Competitive Intelligence, Competitive Landscaping and Mergers & Acquisition across all the Pharma and Biotech industries and geographies. We serve our clients by delivering practical and enduring results and equipping our clients to grow and lead.

For more details please visit: https://www.delveinsight.com/report-store/multiple-sclerosis-market-insights-epidemiology-and-market-forecast-2025

Phone: 919-321-6187

The following two tabs change content below.
Brad Bennett

Brad Bennett

Brad grew up in a small town in northern Iowa. He studied chemistry in college, graduated, and married his wife one month later. They were then blessed with two baby boys within the first four years of marriage. Having babies gave their family a desire to return to the old paths – to nourish their family with traditional, homegrown foods; rid their home of toxic chemicals and petroleum products; and give their boys a chance to know a simple, sustainable way of life. They are currently building a homestead from scratch on two little acres in central Texas. There’s a lot to be done to become somewhat self-sufficient, but they are debt-free and get to spend their days living this simple, good life together with their five young children.
%d bloggers like this: